Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach

Seminars in Diagnostic Pathology

Volumn 23, Issue 1, 2006, Pages 4-14

  Kradin, Richard L ^a   Mark, Eugene J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Asbestos; Immunohistochemistry; Mesothelial hyperplasia; Mesothelioma

Indexed keywords

ASBESTOS; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL MEMBRANE ANTIGEN; FREE RADICAL; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; ASBESTOSIS; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CELL REGENERATION; CHEMICAL CARCINOGENESIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONGESTIVE HEART FAILURE; CYTOPATHOLOGY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS CARCINOMA; FAMILIAL MEDITERRANEAN FEVER; HEMANGIOENDOTHELIOSARCOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INDWELLING CATHETER; INVASIVE CARCINOMA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER CIRRHOSIS; LUNG CARCINOGENESIS; LUNG FIBROSIS; LUNG FUNCTION; LUNG LYMPH FLOW; LUNG METASTASIS; LUNG VENTILATION; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MITOSIS INDEX; MITOSIS RATE; NEPHROTIC SYNDROME; OCCUPATIONAL EXPOSURE; OVARY CARCINOMA; PLEURA BIOPSY; PLEURA EMPYEMA; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PLEURISY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; STOMACH CARCINOMA; SURGICAL ANATOMY; SYNOVIAL SARCOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; THYROID CARCINOMA;

DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURA; PLEURAL DISEASES; PLEURAL NEOPLASMS;

EID: 33748783679     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2006.06.005     Document Type: Article

References (20)

1. Green R.A., and Johnston R.F. Introduction to pleural disease. In: Baum G.L. (Ed). Textbook of Pulmonary Diseases (1974), Little Brown, Boston, MA
2. Hollingshead W.H. Textbook of Anatomy. ed 3 (1974), Harper & Row, Hagerstown, MD
3. Haagensen C.D. General anatomy of the lymphatic system. In: Haagensen C.D. (Ed). The Lymphatics in Cancer (1972), Saunders, Philadelphia, PA 22-41
4. Andrews P.M., and Porter K.R. The ultrastructural morphology and possible functional significance of mesothelial microvilli. Anat Rec 177 (1973) 409-426
5. Wu Y.J., Parker L.M., Binder N.E., et al. The mesothelial keratins. Cell 31 (1982) 693-703
6. Davila R., and Crouch E. Role of mesothelial and submesothelial stromal cells in matrix remodeling following pleural injury. Am J Pathol 142 (1993) 547-555
7. In: Light R., and Lee Y. (Eds). Textbook of Pleural Diseases (2003), Arnold, London
8. Owens M., and Grisham M. Nitric oxide synthesis by rat pleural mesothelial cells-induction by cytokines and lipopolysaccharide. Am J Physiol 265 (1993) 110-116
9. Black L.F. The pleural space and pleural fluid. Mayo Clin Proc 47 (1972) 493-506
10. Churg A., Roggli V., and Colby T.V. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24 (2000) 1183-1200
11. Churg A., Cagle P.T., and Roggli V.L. Tumors of the Serosal Membranes. AFIP Atlas of Tumor Pathology. ed 3 (2006), American Registry of Pathology, Washington DC
12. McCaughey W.T., Kannerstein M., and Churg J. Tumors and Pseudotumors of the Serous Membranes. (2nd series ed). Vol. Fascicle 20 (1985), Armed Forces Institute of Pathology, Washington DC Atlas of Tumor Pathology
13. Attanoos R.L., Suvarna S.K., Rhead E., et al. Malignant vascular tumours of the pleura in "asbestos" workers and endothelial differentiation in malignant mesothelioma. Thorax 55 (2000) 860-863
14. Henderson D.W., Shilkin K.B., and Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110 (1998) 397-404
15. Whitaker D., Henderson D.W., and Shilkin K.B. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 9 (1992) 151-161
16. Mangano W.E., Cagle P.T., Chung A., et al. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol 110 (1998) 191-199
17. Attanoos R.L., Griffin A., and Gibbs A.R. The use of immunohistochemistry in distinguishing reactive form neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43 (2003) 231-238
18. Cury P.M., Butcher P.N., Corrin B., et al. The use of histological and imminohistochemical markers to distinguish pleural malignant mesothelioma ans in situ mesothelioma form reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 189 (1999) 251-257
19. Creaney J., McLaren B.M., Stevenson S., et al. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 84 (2001) 52-56
20. Cagle P.T., Brown R.W., and Lebovitz R.M. p53 immunostaining in the differentiation of reactive process from malignancy in pleural biopsy specimens. Hum Pathol 25 (1994) 443-448